The Proton Pump Inhibitors (PPIs) market is estimated to be valued at US$ 2.9 billion in 2023 and is expected to exhibit a CAGR of 4.30% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Proton pump inhibitors are a class of drugs that reduce the production of stomach acid. These drugs are primarily used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. PPIs work by blocking the enzyme in the stomach lining that produces acid. The increasing prevalence of GERD and the rising adoption of PPIs for its treatment are the major factors driving the growth of the Proton Pump Inhibitors market. The availability of over-the-counter (OTC) PPIs further contributes to the market growth.
Market Dynamics:
The growth of the Global Proton Pump Inhibitors Market is primarily driven by two factors. Firstly, there is a high prevalence of gastroesophageal reflux disease (GERD) worldwide. The increasing incidence of GERD is attributed to factors such as obesity, smoking, and poor dietary habits. Secondly, the adoption of PPIs for the treatment of acid-related disorders is on the rise. PPIs are highly effective in reducing stomach acid production and providing relief from symptoms such as heartburn, acid reflux, and indigestion. The availability of generic PPIs and the convenience of over-the-counter (OTC) PPIs also contribute to the market growth. However, the prolonged use of PPIs may cause side effects such as vitamin B12 deficiency, kidney damage, and increased risk of infections
Segment Analysis:
The proton pump inhibitors market can be segmented based on drug type, distribution channel, and region.
In terms of drug type, the dominant segment in the market is the omeprazole segment. Omeprazole is a widely used proton pump inhibitor and is available both as a prescription drug and over-the-counter medication. It is known for its effectiveness in treating gastroesophageal reflux disease (GERD) and other acid-related disorders. The dominance of the omeprazole segment can be attributed to factors such as its efficacy, availability, and affordability compared to other proton pump inhibitors.
PEST Analysis:
Political: The production and marketing of proton pump inhibitors are subject to various regulations and policies imposed by government bodies. Any changes in regulations regarding drug approvals, pricing, or marketing can impact the market dynamics.
Economic: The economic factors that can influence the proton pump inhibitors market include healthcare expenditure, insurance coverage, and affordability of medications for patients. Economic fluctuations and changes in healthcare policies can affect the demand and accessibility of proton pump inhibitors.
Social: The prevalence of acid-related disorders, such as GERD, is increasing globally. Lifestyle changes, dietary habits, and the aging population contribute to the rising demand for proton pump inhibitors. Awareness campaigns and educational initiatives also play a role in shaping the social dynamics of the market.
Technological: Technological advancements in drug delivery systems and formulations have improved the efficacy and convenience of proton pump inhibitors. Innovations such as delayed-release capsules and extended-release tablets provide better control over acid suppression and enhance patient compliance.
Key Takeaways:
The global proton pump inhibitors market is expected to witness high growth, exhibiting a CAGR of 4.30% over the forecast period, due to increasing cases of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders. The market size for 2023 was estimated to be US$ 2.9 billion.
Regionally, North America is the fastest-growing and dominating region in the proton pump inhibitors market. This can be attributed to the high prevalence of acid-related disorders, well-developed healthcare infrastructure, and increasing healthcare expenditure in the region.
Key players operating in the proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy’s Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR), and Cipla Limited. These key players have a strong presence in the market and invest in research and development activities to introduce new and improved proton pump inhibitors in the market.
Â
